Mydayis Capsule, Extended Release
Product Images NDC 54092-471

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Mydayis (NDC 54092-471). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Mydayis 01)

A line graph depicting the mean concentration (ng/mL) of d-Amphetamine and l-Amphetamine over time (hours) up to 60 hours. The graph compares two formulations: MYDAYIS 37.5 mg and MAS-ER 25 mg plus MAS-IR 12.5 mg. Concentration peaks occur around 8 to 12 hours, with MYDAYIS showing higher d-Amphetamine levels.*

FDA Label Image

Figure 2 (Mydayis 02)

A line graph comparing LS Mean (SE) PERMP Total Scores over time post-dose (hours) between Placebo and Mydayis. The X-axis shows time points from -0.5 to 16 hours, and the Y-axis shows scores from 170 to 330. Two lines represent Placebo (solid line) and Mydayis (dashed line) with error bars, illustrating higher scores for Mydayis at most time points.*

FDA Label Image

Principal Display Panel (12.5 mg Capsule Bottle Label)

Label for MYDAYIS 12.5 mg extended-release capsules, a mixed salts amphetamine oral medication. The label states a package count of 100 capsules and specifies it is a prescription drug by Takeda Pharmaceuticals America, Inc. It includes storage instructions, a warning not to substitute for Adderall XR, and active ingredient details. The label shows an NDC number 54092-468-01 and a barcode.*

FDA Label Image

Principal Display Panel (25 mg Capsule Bottle Label)

Label for Mydayis extended-release capsules, 25 mg strength. The label indicates it is a mixed salts amphetamine product for once-daily oral use. The package contains 100 capsules. It includes the NDC 54092-471-01 and is labeled by Takeda Pharmaceuticals America, Inc. The label also states it is Rx only and advises not to substitute for Adderall XR.*

FDA Label Image

Principal Display Panel (37.5 mg Capsule Bottle Label)

Label for Mydayis 37.5 mg extended-release capsules, a mixed salts single-entity amphetamine product by Takeda Pharmaceuticals America, Inc. The label indicates it contains 100 capsules and is for once-daily oral use. It notes not to substitute for Adderall XR and includes storage instructions and manufacturer details.*

FDA Label Image

Principal Display Panel (50 mg Capsule Bottle Label)

Label for Mydayis 50 mg extended-release capsules, a mixed salts single-entity amphetamine product. The label indicates a 100-capsule package, for once-daily oral use. The product is manufactured by Takeda Pharmaceuticals America, Inc. and includes warnings and storage instructions, alongside the NDC 54092-477-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.